BPC-157: A Research Literature Overview

BPC, the parent peptide, is a ~40-residue protein found in human gastric juice that was identified during research into endogenous gastroprotective compounds at the University of Zagreb in the late 1980s and early 1990s. BPC-157 represents a synthetic, stable 15-residue fragment of this parent sequence selected for its biological activity in early experimental models.

The original characterization of BPC-157 is associated with Predrag Sikiric and collaborators, whose research group has published widely on its activity in preclinical experimental models. Subsequent investigations by independent research groups have expanded the body of published literature beyond gastrointestinal models into musculoskeletal, vascular, and dermal contexts.

Amino Acid Sequence

Chemical Structure

Published peer-reviewed literature has examined BPC-157 in connection with several molecular pathways. The following summarizes investigative directions documented in published studies and does not constitute a claim of human or clinical effect:

• ·Angiogenic signaling. Huang et al. (2015) reported activity in alkali-burn wound healing models, including in-vitro evidence of cell proliferation, migration, and angiogenesis (PMID 25995620).
• ·Nitric oxide pathway / eNOS modulation. Hsieh et al. (2020) characterized modulatory effects on vasomotor tone via the Src–Caveolin-1–eNOS pathway in experimental vascular models (PMID 33051481).
• ·Tendon and collagen-related processes. Staresinic et al. (2003) and Chang et al. (2011) reported observations in transected Achilles tendon models and tendon outgrowth, cell survival, and migration assays (PMIDs 14554208 and 21030672).
• ·Gastric cytoprotection. Sikirić et al. (1993) introduced the BPC family of peptides in the context of the stomach stress-organoprotection hypothesis, an early framework for endogenous gastroprotective compounds (PMID 8298609).

Across the published literature, BPC-157 has been investigated in:

• ·Tendon and ligament repair models (rat Achilles transection, tendocyte assays)
• ·Gastrointestinal mucosal integrity models
• ·Cutaneous and alkali-burn wound healing models
• ·Vascular models examining angiogenesis and nitric oxide signaling
• ·Systemic inflammation and cytoprotection models

BPC-157 is typically supplied as a lyophilized (freeze-dried) powder in sealed vials. Standard laboratory handling considerations from the published literature include:

• ·Storage of lyophilized material: typically at −20 °C for long-term stability.
• ·Reconstitution: typically with bacteriostatic water (BAC water) prior to use in experimental procedures.
• ·Reconstituted storage: at 2–8 °C following reconstitution, used within timeframes defined by the laboratory's experimental protocol.

A research-grade BPC-157 supply should be accompanied by a batch-specific Certificate of Analysis (COA) issued by an independent analytical laboratory. The minimum content to look for on a credible COA includes:

• ·Identity confirmation by mass spectrometry, matching the BPC-157 molecular mass (≈1419.5 Da)
• ·Purity percentage measured by HPLC, typically reported as area percent
• ·Endotoxin screening (LAL assay) for sterile-research applicability
• ·Batch reference number linking the analyzed sample to the supplied vial
• ·Issuing laboratory identity with verifiable contact or portal record

BPC-157 is not approved by Health Canada for human or veterinary use, and no marketing authorization exists for clinical applications. It is supplied and held by laboratories strictly as a research material for in-vitro experimental procedures. Eppix Labs does not provide, and does not endorse, any guidance on human administration or therapeutic application of BPC-157. All material is sold within Canada subject to a written research-use confirmation at the time of purchase.